SANUWAVE Health (OTCMKTS:SNWV – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.
Volatility and Risk
SANUWAVE Health has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.
Earnings & Valuation
This table compares SANUWAVE Health and InspireMD”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SANUWAVE Health | $41.28 million | 5.05 | -$25.81 million | ($1.30) | -18.72 |
| InspireMD | $7.78 million | 9.72 | -$19.92 million | ($0.84) | -2.13 |
InspireMD has lower revenue, but higher earnings than SANUWAVE Health. SANUWAVE Health is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
42.5% of SANUWAVE Health shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 14.9% of SANUWAVE Health shares are held by company insiders. Comparatively, 34.1% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares SANUWAVE Health and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SANUWAVE Health | -1.33% | -23.83% | -20.60% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Analyst Recommendations
This is a breakdown of current ratings for SANUWAVE Health and InspireMD, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SANUWAVE Health | 0 | 0 | 0 | 0 | 0.00 |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
InspireMD has a consensus target price of $5.00, indicating a potential upside of 180.11%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than SANUWAVE Health.
Summary
InspireMD beats SANUWAVE Health on 8 of the 14 factors compared between the two stocks.
About SANUWAVE Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide solution for pain management in sports medicine and physical therapy. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for SANUWAVE Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SANUWAVE Health and related companies with MarketBeat.com's FREE daily email newsletter.
